Q4 2024 · 13F-HR
Novo Holdings A/Sholdings as filed
Filed 2025-02-14 · accession 0000950123-25-002801
$1.65B
Reported value
34
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922908769 | VTI | VANGUARD INDEX FDS | $301.0M | 18.2% | 1,038,550 | Common | SOLE |
| 11271J107 | BN | BROOKFIELD CORP | $160.8M | 9.73% | 2,798,830 | Common | SOLE |
| 88023B103 | TEM | TEMPUS AI INC | $137.6M | 8.33% | 4,074,419 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $133.5M | 8.08% | 5,000,000 | Common | SOLE |
| N07059210 | ASML | ASML HOLDING N V | $114.9M | 6.96% | 165,836 | Common | SOLE |
| 79466L302 | CRM | SALESFORCE INC | $98.3M | 5.95% | 293,901 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $68.4M | 4.14% | 10,114,633 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $62.0M | 3.76% | 1,500,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $61.4M | 3.72% | 750,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $50.0M | 3.03% | 724,666 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $49.1M | 2.97% | 960,215 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $43.1M | 2.61% | 2,250,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $40.5M | 2.45% | 1,520,627 | Common | SOLE |
| 01609W102 | BABA | ALIBABA GROUP HLDG LTD | $38.4M | 2.32% | 452,327 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $33.1M | 2.00% | 1,725,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $32.2M | 1.95% | 490,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $31.5M | 1.91% | 750,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $25.3M | 1.53% | 1,000,000 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $24.0M | 1.45% | 1,663,724 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $23.6M | 1.43% | 2,500,000 | Common | SOLE |
| 51655R101 | — | LANZATECH GLOBAL INC | $21.7M | 1.31% | 15,814,845 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $15.3M | 0.92% | 175,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $13.8M | 0.84% | 1,100,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $13.5M | 0.82% | 2,400,000 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $13.1M | 0.79% | 1,600,000 | Common | SOLE |
| 15678C102 | CBLL | CERIBELL INC. | $8.5M | 0.52% | 328,809 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $8.4M | 0.51% | 1,500,000 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $7.4M | 0.45% | 1,122,581 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $6.9M | 0.42% | 1,850,000 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC. | $6.1M | 0.37% | 4,250,000 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $3.3M | 0.20% | 1,126,915 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $3.1M | 0.19% | 3,354,449 | Common | SOLE |
| 57142B104 | MQ | MARQETA INC | $1.7M | 0.10% | 441,558 | Common | SOLE |
| 36322Q206 | DMRA | GALECTO INC | $464,595 | 0.03% | 99,913 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.